Constellation Pharma Raises $17 Million
Constellation Pharmaceuticals Inc., a Cambridge, Mass.-based developer of drugs that target selective regulators of epigenetic function, has raised $17.2 million in Series B funding. Altitude Life Science Ventures was joined by return backers Third Rock Ventures, The Column Group and Venrock. The company had previously raised $32 million. Constellation Pharma also announced that it has hired Mark Goldsmith as its new CEO. Goldsmith is the former CEO of Cogentus Pharmaceuticals, and most recently was senior executive-in-residence with Prospect Venture Partners.
13 August 2009•4 mins read
